Biopharmaceutical services company Quintiles has appointed Oren Cohen as senior vice president and global head of its Phase I clinical research division, which includes facilities in Overland Park, Kansas (US), London (UK) and Hyderabad (India).
Cohen will leverage Quintiles’ breadth of clinical trial services and expertise in biomarker development to provide clients with an integrated early clinical development platform that reduces overall study costs, simplifies trial management and accelerates development, while ensuring quality and patient safety.
Cohen joined Quintiles as a medical advisor in 2001 and was appointed chief medical and scientific officer (CMSO) in 2004. He is consulting Professor of Medicine at Duke University Medical Center and a Fellow of the Infectious Diseases Society of America.
‘The Phase I clinical research space is changing rapidly, with fewer new molecules entering development and a fundamental shift in target study populations from healthy volunteers to patient groups,’ said Cohen.
‘Biopharma companies are looking for an ally to help them manage these complexities, ensure patient safety and reduce costs, and Quintiles offers best-in-class early clinical development solutions to meet its customers’ needs.’
Quintiles appoints global head of Phase I division
CMSO Oren Cohen takes the role
